Completed PHASE1 INTERVENTIONAL 2-arm NCT01081704

A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects

A Study to Evaluate the Pharmacokinetics of Ustekinumab Following a Single Subcutaneous Administration of 45 mg or 90 mg to Healthy, Chinese, Male Subjects

Sponsor: Centocor, Inc.

Conditions Healthy

Interventions ustekinumab

Updated 5 times since 2017 Last updated: May 26, 2014 Started: Oct 31, 2009 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Centocor, Inc. leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centocor, Inc.

Data source: Centocor, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China